Imatinib's Effectiveness in Metastatic Melanoma
Author Information
Author(s): Ugurel S, Hildenbrand R, Zimpfer A, La Rosée P, Paschka P, Sucker A, Keikavoussi P, Becker J C, Rittgen W, Hochhaus A, Schadendorf D
Primary Institution: German Cancer Research Center Heidelberg and University Hospital of Mannheim
Hypothesis
Does imatinib show clinical efficacy in patients with metastatic melanoma based on the expression of its target molecules?
Conclusion
The study found no clinical efficacy of imatinib in patients with advanced metastatic melanoma.
Supporting Evidence
- 16 out of 18 patients experienced tumor progression after 2–8 weeks of treatment.
- The median overall survival was 3.9 months.
- Imatinib did not show any antiproliferative effect in vitro on melanoma cell lines.
- 75% of tumor specimens stained positive for c-kit, but this did not correlate with treatment response.
- Severe toxicities occurred in 28% of patients, leading to dose modifications.
Takeaway
Doctors tested a medicine called imatinib on patients with a serious skin cancer, but it didn't help them get better.
Methodology
This was a two-centre phase-II trial where 18 patients with treatment-refractory advanced melanoma received imatinib and were monitored for response and survival.
Potential Biases
Potential selection bias due to the inclusion criteria focusing on patients with advanced disease.
Limitations
The study had a small sample size and did not include a control group.
Participant Demographics
Median age of participants was 54.2 years, with a mix of male and female patients.
Statistical Information
Confidence Interval
2.8–5.3 months
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website